Validating quantitative PCR assays for cell-free DNA

detection without DNA extraction: Exercise induced

kinetics in systemic lupus erythematosus patients

- Elmo W.I. Neuberger¹, Alexandra Brahmer¹, Tobias Ehlert¹, Katrin Kluge¹, Keito 5
- F.A. Philippi¹, Simone C. Boedecker², Julia Weinmann-Menke² and Perikles 6
- Simon^{1,*} 7

1

2

3

4

13

28

- 8 ¹Department of Sports Medicine, University of Mainz, Mainz, Germany. Albert-Schweitzer Str. 22, 55128 Mainz,
- 9
- 10 ²Department of Rheumatology and Nephrology, University Medical Center Mainz, Germany. Langenbeckstr. 1,
- 55101 Mainz, Germany. 11
- 12 * simonpe@uni-mainz.de

ABSTRACT

- 14 Circulating cell-free DNA (cfDNA) has been investigated as a screening tool for many diseases. To avoid
- expensive and time-consuming DNA isolation, direct quantification PCR assays can be established. 15
- 16 However, rigorous validation is required to provide reliable data in the clinical and non-clinical context.
- 17 Considering International Organization for Standardization, as well as bioanalytical method validation
- 18 guidelines we provide a comprehensive procedure to validate assays for cfDNA quantification from
- 19 unpurified blood plasma. A 90 and 222 bp assay was validated to study the kinetics of cfDNA after
- 20 exercise in patients with systemic lupus erythematosus. The assays showed ultra-low limit of
- quantification (LOQ) with 0.47 and 0.69 ng/ml, repeatability ≤ 11.6% (95% CI: 8.1-20.3), and 21
- 22 intermediate precision ≤ 12.1% (95% CI: 9.2-17.7). Incurred sample reanalysis confirmed the precision
- 23 of the procedure. The additional consideration of pre-analytical factors shows that centrifugation speed
- 24 and temperature do not change cfDNA concentrations. In SLE patients cfDNA increases ~2 fold after
- 25 all out walking exercise, normalizing after 60 min of rest. The established assays allow reliable and cost-
- efficient quantification of cfDNA in minute amounts of plasma in the clinical setting and can be used as 26
- 27 a standard to control pre-analytical factors including cfDNA losses during purification.

Introduction

- 29 Circulating cell-free DNA (cfDNA) is recognized to have reasonable prognostic or diagnostic potential in several
- 30 pathological diseases including cancer, sepsis, and autoimmune diseases such as SLE^{1,2}. In 1966 Tan et al.
- described high levels of cfDNA in serum of SLE patients³. Since that time, a plethora of studies confirmed elevated 31
- 32 cfDNA concentrations in serum and plasma of SLE patients with active or inactive disease (reviewed in²). In
- 33 patients with autoimmune disease, high levels of cfDNA are considered to be a relevant antigen for auto anti-body
- development⁴⁻⁶. Intriguingly, cfDNA concentrations increase about 10 fold during all out exercise, showing a half-34
- 35 life of ~15 min in the healthy population⁷⁻⁹. While regular physical exercise is recommended for SLE patients, and
- 36 several studies provided reasonable evidence that regular exercise reduces fatigue and increases cardiovascular
- 37 fitness in SLE patients¹⁰, the kinetics of cfDNA during exercise in SLE patients are still unknown. A minimal
- invasive and cost-efficient assay is a valuable tool to monitor cfDNA concentrations, which might be indicative 38
- 39 for overtraining or disease remission^{11,12}.
- 40 Most cfDNA quantification assays require pre-analytical DNA extraction¹³. A process, which is costly, time
- 41 consuming and has been shown to lead to variable loss of cfDNA depending on the extraction method
- 42 employed^{14,15}. To avoid cfDNA isolation, direct quantification assays have been established^{14,16}. Using multilocus
- 43 primers, which bind various sites in the human genome, a sufficient sensitivity can be reached. The hominoid
- 44 specific long interspersed element 1 (LINE1) family 2 (L1PA2) is a suitable target, according to its abundance and 45 SNOTE OTHE Preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

A major prerequisite for reliable cfDNA detection is the evaluation of the assay performance. In 2019 the 46 47 International Organization for Standardisation (ISO) published a guideline which comprehensively specifies the 48 requirements for evaluating the performance of quantification methods for nucleic acid target sequences for quantitative real-time PCR (qPCR) and digital PCR (dPCR)¹⁸. 49

Based on previous work¹⁹, we describe the validation of reliable qPCRs assays for the quantification of cfDNA. Considering the relevant guidelines we emphasize the specificity, precision, including repeatability and intermediate precision, limit of detection (LOD), limit of quantification (LOQ), linearity, as well as incurred sample reanalysis. Since cfDNA typically shows a length of about 166bp²⁰, the combination of a 90bp assay and 222bp assay enables the evaluation of DNA integrity^{21,22}.

The assays could be applied successfully to quantify cfDNA samples in the clinical context. We show that exercise induced cfDNA increases start to decline after 30 min in SLE patients, normalizing after 60 - 90 min. Since elevated cfDNA concentrations have been discussed to possibly trigger enhanced inflammation or the production of anti-ds-DNA antibodies, low increases during and rapid decreases after exercise are rather positive aspects of cfDNA kinetics during exercise in SLE patients. The direct quantification enables a time and cost saving quantification assay, which further could be standard assay to control for pre-analytical factors including cfDNA losses during purification. Furthermore, according to its high sensitivity the assay can be used to study cfDNA in other body liquids, cell culture supernatant.

Methods

50 51

52

53

54

55

56

57

58

59

60

61 62

63 64

65

66

67

68 69

70

71

72

73

74

75

Ethics approval and exercise testing. SLE patients were recruited at the Department of internal Medicine, University Medical Center, Mainz, Germany. Patients with a stable immunosuppressive medical therapy and no active lupus nephritis were asked to participate in an exercise intervention study (ClinicalTrials.gov Identifier: NCT03942718, date of first registration 08.05.2019)²³. The registered study aims to evaluate the effects of a 12week exercise program on cardiorespiratory fitness. In the context of this assay validation study the samples from the initial examination time point were used to study the kinetics of cfDNA in SLE patients during and after acute exercise. The experimental procedures were approved by the Human Ethics Committee of Rhineland-Palatine and were in line with the Declaration of Helsinki of the World Medical Association. All participants gave their informed consent for study participation. A total of 28 eligible study participants performed a stepwise exercise test until volitional exhaustion with a modified walking protocol²³. Speed and elevation of the treadmill were increased stepwise every three minutes until the participants stopped the test volitionally. Heart rate and respiratory gas exchange were monitored continuously.

Characteristics of the study subjects	Mean	± SD
Age (years)	49,42	8,70
Weight (kg)	77,53	18,54
Height (cm)	166,43	8,34
BMI	27,96	6,07
SLEDAI	6,50	4,42
VO2peak (ml/min/kg)	24,34	5,04
Exercise time until exhaustion (min)	13,61	3,67
Medication, n (%)	22 (78%)	
Steroids	17 (61%)	
Hydrochloroquine	14 (50%)	
Belimumab	4 (14%)	
Cyclophosphamide	1 (3%)	
Azathioprine	2 (7%)	
Mycophenolate mofetil	7 (25%)	
No medication, n (%)	6 (21%)	

Table 1. SLE patients' characteristics. SLEDAI = Systemic Lupus Erythematosus Disease Activity Index, BMI = 76 77 Body Mass Index.

- 78 **Blood sample collection.** Venous blood samples from the cubital vein were collected before, directly after,
- 79 and 90 min after the exercise test. The utilized blood collection products are listed in Supplementary Table S1.
- 80 The samples were centrifuged immediately after drawing two times at 2500 x g for 15 min at room temperature
- (RT), to collect platelet-free plasma.²⁴ Capillary blood samples were collected from the fingertip and stored at 4°C 81
- before centrifugation at 600 x g for 10 min. For comparison of centrifugation protocols, venous blood samples 82
- 83 were centrifuged as indicated.
- 84 Assay validation material. Linearity and accuracy of the direct quantification method was tested on a custom-
- 85 made 401-bp fragment from the L1PA2 family (Supplementary Table S2). The fragment was synthesized by
- 86 Eurofins MWG Operon, cloned into a pEX-A plasmid (Eurofins MWG Operon), amplified in bacteria before DNA
- 87 isolation with QIAprep Spin Miniprep Kit (Qiagen, Hilden, Germany). After EcoRI restriction the 401 bp 88 Fragment was gel purified with QIAquick Gel Extraction Kit (Qiagen, Hilden, Germany). The concentration was
- 89 determined with a NanoDrop 3300 fluorospectrometer (Thermo Fisher Scientific, Inc., Waltham, MA) using
- 90 Quant-iTTM PicoGreen dye (Thermo Fisher Scientific, Inc., Waltham, MA). For precision studies, a pool of venous
- 91 plasma from six healthy subjects before (PRE exercise sample) and after exercise (POST exercise sample) was
- 92
- 93 Sample preparation and qPCR. Plasma samples were diluted 1:10 in UltraPureTM DNase/RNase-Free H₂O
- 94 (Invitrogen, Waltham, MA). For the qPCR, 2 µl of the diluted plasma, were mixed with 12 µl master-mix, 1 µl
- 95 primer mix, and measured in triplicates with a final volume of 5 µl. The primer sequences are listed in
- 96 Supplementary Table S3. The final concentrations in the PCR reaction are 1.2X HiFi buffer (BioCat, Heidelberg,
- 97 Germany), 0.3 mM of each dNTP (Carl Roth, Karlsruhe, Germany), 0.15X SYBR Green (Sigma, Taufkirchen,
- 98 Germany), 0.04 IU Velocity Polymerase (BioCat, Heidelberg, Germany), and 140 nM of each primer. For
- 99 amplification a CFX384 system with the following protocol was used: 98°C for 2 min followed by 35 cycles of
- 100 95°C for 10 sec (denaturation) and 64°C for 10 sec (annealing/extension) including the plate read. A melt curve
- 101 from 70 – 95°C with 0.5 °C increments for 10 sec finished each run. If the triplicates of the samples show a SD
- 102 Cq > 0.4, native plasma samples were re-diluted and reanalyzed.
- 103 In silico calculation of L1PA2 copy numbers per genome. To determine the number of targets for the
- 104 L1PA2 90bp and L1PA2 222bp primer pairs in the human genome (GRCh38/hg38), the UCSC Genome Browser
- 105 In-Silico PCR tool was used (https://genome.ucsc.edu/cgi-bin/hgPcr). The Max Product Size (Maximum size of
- 106 amplified region) was set to 660 bp, which equals the predicted maximal amplification rate of the polymerase
- 107 during 10s amplification. Min Perfect Match (Number of bases that match exactly on 3' end of primers) was set to
- 108 19 bp. The predicted sequences per chromosome and the length distribution are provided in Supplementary Fig.
- 109 S4 and Table S5.
- Calculation of cfDNA concentration in plasma samples. To determine the cfDNA concentration in 110
- (ng/ml) from the Cq values of samples the following calculation is applied: $ng/ml \triangleq pg/\mu l = 10^{(Cq intercept)/slope} / 5\mu l$ 111
- /(1/75) * 3.23 pg/(3416 for L1PA2 90bp or 3237 for L1PA2 222bp). Using the slope and the intercept from the 112
- 113 validated standard curve the total number of copies per 5µl qPCR reaction are calculated. A division by 5 results
- 114 in copy numbers per µl. The copy numbers per µl plasma are calculated by considering the total dilution factor of
- 115 plasma 1/75 (plasma dilution 1/10 and qPCR dilution: 2µl template per 15µl reaction). The copy number per µl is
- 116 dived by the number of predicted sequences in the human genome (3416 for the L1PA2 90bp and 3237 for the
- 117 L1PA2 222bp). The result reflects the number of genome equivalents (GE) per ml plasma. The resulting GE are
- 118 multiplied with 3.23 pg (the expected weight of a haploid genome²⁵) to calculate the pg concentration per µl
- 119 plasma, equaling ng/ml.
- 120 PCR run interplate calibration. The CFX384 real-time system calculates the C_q values based on the crossing
- 121 point of the fluorescence traces with an auto-calculated threshold line. The threshold is dependent on the total
- 122 number of samples and fluorescence intensity. To correct for inter-plate differences, two reference samples are
- measured in each run. For the analysis of the results, the threshold is adapted so that the mean of the Cq values of 123
- the reference samples equals the pre-defined mean $C_{\mathfrak{q}}$ value. The pre-defined mean $C_{\mathfrak{q}}$ value is based on the mean 124
- autocalculated Cq values of 10 PCR runs from two different operators. The indicated reference samples are a pre-125
- 126 and a post-exercise plasma samples from a single subject. Typical amplification curves are shown in
- 127 Supplementary Fig. S6.
- 128 **Determination of assay performance.** For the determination of the *dynamic range, assay linearity, LOD and*
- 129 LOO the purified L1PA2 DNA fragment was spiked into mouse plasma (1:10 final dilution). Mouse plasma is a
- 130 relevant sample matrix and does not contain the human specific L1PA2 sequences. Three independent standard
- 131 curves were prepared for each of the assays on different days. Each concentration (1 x 10⁶ - 25 copies per well)
- 132 was pipetted in septet replicates (Fig. 1). H₂O and mouse plasma NTC controls, as well as the reference samples 133 were pipetted on each plate. For the determination of the LOQ the results from all standard curves were combined
- 134 to generate imprecision profiles using the Variance Function Program VFP (v1.2) with R (v3.6.3) (Fig. 1). The

- 135 LOD was defined as the lowest concentration of the target analyte which can be detected with a 95% detection
- 136 rate^{26,27}. Where applicable, the CLSI guideline EP17-A2 were used, defining a limit of blank (LOB) = Mean_{copy}
- $_{number \, blank} + 1.645 \, x \, SD_{copy \, number \, blank} \, and \, LOD = LOB + 1.645 \, x \, SD_{low \, copy \, number \, sample}^{28}$. 137
- 138 Assay imprecision. To evaluate the influence of the plasma dilution process, 20 replicates of the PRE and POST
- 139 samples were measured in a single run. 10 replicates were measured from the same diluted plasma pool and 10
- 140 replicates were diluted 1:10 uniquely. The coefficient of variation (CV) was calculated with the formula CV =
- 141 (Standard Deviation / Mean) * 100. To estimate the repeatability and intermediate precision 20 replicates were run
- 142 in duplicates over 10 different PCR runs.
- 143 Direct quantification compared to kit isolation. To compare the concentration of cfDNA before and after DNA isolation
- 144 using custom DNA extraction kits, plasma was aliquoted in 15 tubes and frozen at -20°C. Five of the aliquots (1ml
- 145 plasma) were purified with the QIAamp® Circulating Nucleic Acid kit (Qiagen, Hilden, Germany) (Purification
- 146 kit 1), and the NucleoSnap cfDNA kit for cell-free DNA from plasma (Macherey-Nagel, Düren, Germany)
- 147 (Purification kit 2), respectively. Additionally, 5 aliquots of 400µl plasma were isolated with the QIAamp DNA
- 148 Blood Mini Kit (Qiagen, Hilden, Germany) (Purification kit3). All samples were eluted in H₂O (1/10 of input
- 149 volume). For the direct quantification, from each plasma aliquot a dilution was prepared. All samples were
- 150 measured after a single freeze thaw cycle.
- 151 Incurred sample reanalysis: To verify the reliability of the cfDNA concentration in the study samples, a subset of two
- 152 samples from each qPCR run was re-analyzed in the subsequent run. The percentage difference of the cfDNA
- 153 concentration between the first and the repeated measurement is determined with the following equation: (Repeat
- 154 First) / Mean * 100, according to the Bioanalytical Method Validation Guidance for Industry²⁹.
- 155 Storage stability: To determine the stability of plasma dilutions 20 samples of a former study were reanalyzed after
- > 2 month of storage at -20°C. To determine the storage stability of whole blood before centrifugation, four venous 156
- 157 and capillary samples were taken consecutively and centrifuged at 2500 x g for 10 min directly after blood drawing,
- 158 after 60 min, 90 min, or 180 min.
- 159 Data analysis. The qPCR analysis was performed with the CFX Manager software Version: 3.1.1517.0823.
- 160 Python (v3.7.6) with 'matplotlib' (v3.1.1), and 'seaborn' (v0.9.0), and R (v3.6.3) with ggplot2 (v3.3.2) were used
- for descriptive analysis. The imprecision calculation were performed using the R 'VFP' package (v1.2). Linear 161
- mixed models were conducted with the 'lme4' package (v1.1.23), to determine if capillary and venous cfDNA 162
- 163 levels differ and respond differently to exercise. The 'emmeans' package (v1.4.8) was used to compute tukey
- 164 corrected P values. Pearsons r or Spearman's rho were calculated for normally or not normally distributed data,
- 165 respectively.

166

Results

- Characteristics of SLE patients. A total of 28 SLE patients (27 female, 1 male) were eligible for the study 167
- and participated in the performance diagnostic test without adverse events. The patients' characteristics (Table 1) 168
- 169 indicate a higher body mass index (BMI), and lower physical fitness (VO2peak) compared to the healthy
- 170 population³⁰.
- 171 Assay performance. Dilution linearity and dynamic range. The independent LOQ curves show similar slope and
- 172 y-intercept (Fig. 1). The efficiencies for the different standard curves are slightly lower than 90%. Ranging between
- 173 87.77 and 89.25% for the L1PA2 90bp assay and between 84.19 and 88.75% for L1PA2 222bp assay.
- 174 LOD and LOQ. All replicates of the low copy samples (25 copies) were detectable with the L1PA2 90bp and the
- 175 L1PA2 222bp assay, not reaching LOD (Fig. 1). Of note, as shown in Supplemental Fig. S6, the NTCs of the
- 176 L1PA2 90bp assay produce some background signal, which needs to be distinguishable from low copy samples.
- 177 Since the data were normally distributed with homogenous variances, the LOB and LOQ were calculated according
- 178 to the CLSI guideline²⁸. The L1PA2 90bp assay shows a LOB of 8.39 copies and LOD of 18.59 copies. The LOQ,
- 179 which was derived from the imprecision profile was 32.5 copies for the L1PA2 90bp and 59.26 copies for the
- 180 L1PA2 222bp (Fig. 1), equaling a concentration of 0.47 ng/ml and 0.69 ng/ml, respectively.
- 181 Imprecision studies. The CVs were similar between the pooled or uniquely diluted plasma samples with 7.32% and
- 182 8.77% (PRE exercise sample), and 6.67% or 8.51% for the POST exercise sample (L1PA2 90bp assay) (Fig. 2a).
- 183 For the L1PA2 222bp the CVs were 9.17 and 9.37% for the PRE exercise and 7.55 and 8.56 for the post exercise
- 184 samples. The precision calculation for the measurements of the PRE and POST samples in repeated runs, resulted
- 185 in a repeatability $\leq 11.59\%$ (95% CI: 8.10 – 20.34) for the two assays.




Figure 1. Standard curves and imprecision profiles for the L1PA2 90bp assay (a, b) and the L1PA2 222bp assay (c, d). Three independent standard curves, with septets per concentration were prepared for each assay. The imprecision profiles were calculated with the formulas: $\sigma^2 = 31.37 + 0.011 \times U^{1.975}$ and $\sigma^2 = (6.10 + 0.097 \times U)^2$ for the 90 bp (b) and 222 bp assay (d), respectively. The grey area indicates the quantification range of cfDNA concentrations in this study. Cq = cycle quantification value, LOQ = lower limit of quantification, CV = coefficient of variation.

186

187 188

189

190 191

192

193 194

195

196

197

198

199

200




Figure 2. Precision of the L1PA2 90bp assay. (a) The same pool of plasma dilution of a low and high concentration sample was measured 10 times (P1), the same plasma was individually diluted 10 times (P2), the plasma dilution was measured in 10 consecutive runs in duplicate (P3 = mean of duplicates after inter-plate calibration, P4 = mean of duplicates before inter-plate calibration). The dashed lines indicate $\pm 20\%$ of the nominal mean of conditions P1-3. Incurred sample reanalysis. From each run of the study samples, two samples were reanalyzed. (b) Correlation of the first and second measurement. (c) Percentage difference between original and second measurement.

Inter-run calibration. After the inter-run calibration the intermediate precision, calculated from 10 consecutive qPCR runs, reduced for the L1PA2_90bp assay from 23.80% (95% CI: 17.96-35.31) to 11.62% (95% CI: 8.77-17.22) (PRE sample), and from 24.75% (96% CI: 18.47-37.51) to 8.46% (95% CI: 6.40-12.45) (POST sample) (Fig. 2a). For the L1PA2_222bp assay the intermediate precision reduced for the PRE sample from 18.01% (95% CI: 12.58-31.61) to 12.97 (95% CI: 8.90-18.24), and the POST sample from 21.54% (95% CI: 16.04-32.78) to 12.06% (95% CI: 9.16-17.69).




Figure 3. Direct quantification of cfDNA compared to DNA purification and influence of centrifugation speed and temperature on cfDNA concentration. (a) Plasma aliquots of the same sample were directly quantified or analyzed after DNA isolation with custom DNA isolation kits, to determine the cfDNA concentration (left) and the fragmentation index (right). (b) From different subjects (S1-S3) four samples were consecutively collected in different blood containers, centrifuged at 600 x g or 2500 x g for 10 min and measured with the L1PA2_90bp assay. (c) From each subject a single blood sample was collected and centrifuged consecutively at indicated speed at 4°C or room temperature (RT) and measured in duplicate, mean values are illustrated.

Stability of plasma dilutions. Plasma samples can be stored at -20° C or -80° C for years without affecting cfDNA concentration³¹. To determine the stability of 1:10 plasma dilutions, 20 diluted samples were re-analyzed with the L1PA2_90bp assay after storage for > 2 month at -20° C. cfDNA concentrations did not differ significantly (P = 0.35) and no degradation was obvious after a repeated freeze-thaw cycle. Prolonged storage of whole blood (up to 180 min) before centrifugation did not lead to relevant cfDNA concentration changes (Supplementary Fig. S7).

Effects of cfDNA purification. The use of specific DNA isolation kits for cfDNA isolation from plasma (Purification kit 1 and 2) slightly affects the cfDNA concentration and DNA integrity (Fig. 3a). During the isolation process about 12% (\pm 9.5) and 23% (\pm 6.2) are lost with Purification kit 1 or 2, respectively. A kit for whole blood DNA isolation (Purification kit 3) leads to relevant DNA losses of about 84% and increased DNA integrity, which indicates a loss of short DNA fragments.

Influence of centrifugation speed or temperature. As shown in Fig. 3b and 3c, centrifugation speed and temperature does not influence the cfDNA concentration in venous plasma. The concentration differences are within the assay precision of the L1PA2 90bp assay. Notably, as shown in Fig. 3b in one subject the first of 4 taken samples shows higher cfDNA levels (independent from centrifugation speed), indicating that the first sample should be discarded.

226

227

228

229

230

231

232

233

234

235

236

237

238

239 240

241

242

243

244

245 246

247

248

Incurred sample reanalysis. During the course of the study ~17% of the SLE study samples were reanalyzed. The cfDNA concentrations correlate well between first and repeated analysis (r= 0.925, p<0.0001) (Fig. 2b). Among the reanalyzed samples, 5 samples (9.16%) measured with the L1PA2 90bp assay show a difference > ±30% between the initial and the repeated measurement (Fig. 2c). 25.53% of the reanalyzed samples show a difference > ±30% between first and repeated measurement in the L1PA2 222bp assay.

cfDNA measurement in study samples. A total of 280 study samples were measured with each of the assays. Seven (2.5%) of the samples measured with the L1PA2 90bp, and 21 (7.5%) measured with the L1PA2 222bp assay showed repeatedly high SD of Cq values and were declared to be not measurable.




Figure 4. Kinetics of venous and capillary cfDNA measured with the L1PA2 90bp assay before and after exercise. Differences of cfDNA from PRE samples during and after exercise in venous plasma samples (a) and capillary plasma samples (b) (median and 95% CI are illustrated). (c) Boxplots of cfDNA concentration in capillary and venous plasma samples. (d) Correlation between venous and capillary cfDNA concentrations.

Kinetics of cfDNA after exercise. The estimated means of the SLE patients' venous cfDNA levels increased significantly ~ 2.1 fold from 13.9 ng/ml (95% CI: 10.4–18.8) to 29.6 ng/ml (95% CI: 22.0–39.9) and decreased to 14.1 ng/ml (95% CI: 10.5-19.9) 90 min after walking exercise (Fig. 4c). Similarly, the capillary samples increased significantly ~ 2.2 fold from 11.1 ng/ml (95% CI: 8.0-15.4) to 24.8 ng/ml (95% CI: 17.9-34.4) and decreased to

13.6 ng/ml (95%CI: 10.0-18.4). After 90 min the concentrations declined to PRE exercise values again. A detailed results table for the multiple comparisons is given in Supplementary Table S8 and S9. Fig. 4a and 4b display the differences of cfDNA levels from the PRE value.

The comparison between venous and capillary cfDNA concentrations (Fig. 4d) shows an overall correlation of R^2 = 0.774, p < 0.0001 (dotted black line). The correlation between venous and capillary samples is higher for the PRE exercise $(R^2 = 0.933, p < 0.0001)$, and +90 min samples $(R^2 = 0.974, p < 0.0001)$ compared to POST exercise samples ($\rho = 0.726$, p = 0.0002).

As indicated in Fig. 5a cfDNA remains increased until 30 min post exercise. The linear regression across all time points (black line) indicates a half-life of ~30 min (slope = -0.167, intercept = 16.87). Between 30 min post exercise and 60 min post exercise the cfDNA concentrations show the highest decay rate. The linear regression between +30 and +60 min indicates a half-life of about ~ 15 min (red regression line, slope = -0.315, intercept = 23.61). The fragmentation index, calculated as the quotient of the concentrations of the longer L1PA2 222bp fragments and the shorter L1PA2 90bp fragments, increases from 0.33 ± 0.23 ng/ml at the PRE time point to 0.35 ± 0.23 ng/ml post exercise, and decreases to 0.32 ± 0.26 ng/ml after 90 min (Fig. 5b).




Figure 5. cfDNA decay and fragmentation index. (a) The 'loess' regression line (blue, with 95% CI in grey) indicates that levels of cfDNA remain increased until 30 min post exercise and decrease most strongly between +30' and +60' (red linear regression line). (b) Distribution of the fragmentation index of all study samples.

Discussion

249

250

251

252

253

254 255

256

257

258

259

260

261 262

263

264 265

266

267

268

269

270 271

272

273 274

275

276

277

278

279

280

281 282

283 284 During the last years, cfDNA has been increasingly studied for its prognostic or diagnostic potential in various clinical fields^{2,32,33}. A prerequisite to use cfDNA levels for monitoring applications is to ensure reliable and reproducible quantification³⁴. The ISO guideline ISO 20395:2019 specifies the requirements for evaluating the performance of quantification methods for nucleic acid target sequences for qPCR and dPCR experiments¹⁸. The guideline provides a profound background to validate qPCR assays, comprising the MIQE and relevant CLSI guidelines. To compare the cfDNA concentrations of the SLE study samples over multiple runs, we implemented an inter-plate calibration procedure which allows reliable comparison of cfDNA concentrations between different qPCR runs. To ensure the reproducibility of the direct quantification method in plasma of SLE patient who receive medication we applied incurred sample re-analysis, to verify the concentration of cfDNA³⁵.

The, established L1PA2_90bp and L1PA2_222bp qPCR assays enable reliable direct quantification of cfDNA in minute amounts of plasma samples. A unique advantage of the assays is that the plasma samples do not need to be purified. A step which is time and cost consuming and can introduce errors in the quantification process. As shown in Fig. 3a, especially DNA isolation kits, which are not specifically established to isolate cfDNA from plasma can lead to reduced cfDNA concentrations and the loss of short DNA fragments^{15,36}. Importantly, our assay could be used as a standard to control for DNA losses and to estimate the integrity of the isolated DNA samples.

At the time, there is no defined number of replicates to determine LOQ, whereas a minimum of 10 replicates in total per concentration is recommended¹⁸. For the precision studies, pooled PRE and POST exercise plasma were

- 285 used representing low and high copy number samples. The CV for all samples, were below 10%, indicating
- 286 sufficient precision to clearly discriminate the effects of exercise. To determine the relative repeatability and
- 287 relative run-to-run variation standard deviations, duplicates of the low and high copy plasma pools were measured
- 288 in 10 consecutive qPCR runs. All precision estimations were below 12.1%.
- 289 Whenever samples are not analyzed in the same run, it is important to take inter-run calibration into account. For
- 290 qPCR assays this is of unique importance because the relationship between quantification cycle and relative
- 291 quantity is run dependent³⁷. The baseline correction of each qPCR run is depending on the total number of samples
- 292 and the fluorescence intensity³⁷. Here, we provided experimental proof that the use of two inter-run calibrators
- 293 reduced the intermediate precision between 8.07% and 16.29%.
- A number of pre-analytical variables can affect the results of cfDNA measurement 15,38. As reviewed by Ungerer 294
- 295 et al. 15 the influence of centrifugation speed is still discussed controversially, whereas a second centrifugation step
- 296 is recommended³⁸. Our results indicate that centrifugation at 600 x g compared to 2500 or 16.000 x g does not 297 relevantly influence cfDNA concentrations. The detectable differences were within the assay precision. Notably,
- 298 we avoided untarred centrifuges, and disturbances of the cell pellet during pipetting. Similar to other studies we
- 299 did not detect cfDNA changes after prolonged storage of EDTA whole blood samples to several hours^{39,40}.
- 300 According to the simpler, and less invasive sampling technique, capillary plasma samples are a reasonable sample
- 301 source, which can be collected more frequently. The comparison of venous and capillary samples shows high
- 302 congruence. Notably, repeatedly collected capillary samples show a higher variance of cfDNA concentrations
- 303 compared to venous samples, which is not related to assay imprecision (as indicated in Supplementary Fig. S7).
- 304 The reason is not clarified in detail, and the intra-individual variance needs further systematic evaluation.
- Studies indicate that SLE patients show higher cfDNA concentrations compared to the healthy population, and 305
- that cfDNA concentrations are related to disease activity^{12,41}. Exercise is recommended for the treatment of SLE 306
- 307 patients⁴². However, the kinetics of cfDNA after exercise has not been studied. After walking until exhaustion, the
- 308 studied SLE patients showed lower fold-changes compared to healthy subjects, which is likely related to exercise intensity, time until exhaustion, and total energy expenditure^{7,14,43}. cfDNA concentrations normalized 60-90 min 309
- 310 after exercise in most of the patients (Fig. 4 and Fig. 5), showing no significant differences from the PRE cfDNA
- values (Supplementary Tables S8 and S8). Since elevated cfDNA concentrations have been discussed to possibly 311
- trigger enhanced inflammation⁴⁴, or the production of anti-ds-DNA antibodies⁵, low increases and a rapid decrease 312
- 313 are positive aspects of cfDNA kinetics in SLE patients. With the established time and costs efficient assay we
- 314 determined the cfDNA kinetics in exercising SLE patients for the first time, underlining that exercise does not has
- 315 a negative impact on the levels of cfDNA.

References

316

317

- 318 1. Bronkhorst, A. J., Ungerer, V. & Holdenrieder, S. The emerging role of cell-free DNA as a molecular 319 marker for cancer management. Biomol. Detect. Quantif. 17, 100087 (2019).
- 320 2. Duvvuri, B. & Lood, C. Cell-Free DNA as a Biomarker in Autoimmune Rheumatic Diseases. Front. 321 Immunol. 10, 502 (2019).
- Tan, E. M., Schur, P. H., Carr, R. I. & Kunkel, H. G. Deoxybonucleic acid (DNA) and antibodies to DNA 322 3. 323 in the serum of patients with systemic lupus erythematosus. J. Clin. Invest. 45, 1732–1740 (1966).
- 324 4. Sisirak, V. et al. Digestion of Chromatin in Apoptotic Cell Microparticles Prevents Autoimmunity. Cell 325 **166**, 88–101 (2016).
- Bai, Y., Tong, Y., Liu, Y. & Hu, H. Self-dsDNA in the pathogenesis of systemic lupus erythematosus. 326 5. Clin. Exp. Immunol. 191, 1-10 (2018). 327
- 328 6. Rekvig, O. P. The dsDNA, Anti-dsDNA Antibody, and Lupus Nephritis: What We Agree on, What Must 329 Be Done, and What the Best Strategy Forward Could Be. Front. Immunol. 10, (2019).
- 330 7. Beiter, T., Fragasso, A., Hudemann, J., Nieß, A. M. & Simon, P. Short-Term Treadmill Running as a Model for Studying Cell-Free DNA Kinetics In Vivo. Clin. Chem. 57, 633-636 (2011). 331
- Breitbach, S., Sterzing, B., Magallanes, C., Tug, S. & Simon, P. Direct measurement of cell-free DNA 332 8. 333 from serially collected capillary plasma during incremental exercise. J. Appl. Physiol. 117, 119-130 334 (2014).

perpetuity.

It is made available under a CC-BY 4.0 International license .

- 335 9. Dennis Lo, Y. M. *et al.* Rapid clearance of fetal DNA from maternal plasma. *Am. J. Hum. Genet.* **64**, 218–336 224 (1999).
- 337 10. O'Dwyer, T., Durcan, L. & Wilson, F. Exercise and physical activity in systemic lupus erythematosus: A systematic review with meta-analyses. *Semin. Arthritis Rheum.* 47, 204–215 (2017).
- Fatouros, I. G. *et al.* Cell-Free Plasma DNA as a Novel Marker of Aseptic Inflammation Severity Related to Exercise Overtraining. *Clin. Chem.* **52**, 1820–1824 (2006).
- Tug, S. *et al.* Correlation between cell free DNA levels and medical evaluation of disease progression in systemic lupus erythematosus patients. *Cell. Immunol.* **292**, 32–39 (2014).
- Meddeb, R., Pisareva, E. & Thierry, A. R. Guidelines for the Preanalytical Conditions for Analyzing Circulating Cell-Free DNA. *Clin. Chem.* **65**, 623–633 (2019).
- 345 14. Breitbach, S. *et al.* Direct Quantification of Cell-Free, Circulating DNA from Unpurified Plasma. *PLoS One* **9**, e87838 (2014).
- Ungerer, V., Bronkhorst, A. J. & Holdenrieder, S. Preanalytical variables that affect the outcome of cell-free DNA measurements. *Crit. Rev. Clin. Lab. Sci.* **57**, 484–507 (2020).
- Umetani, N. *et al.* Increased Integrity of Free Circulating DNA in Sera of Patients with Colorectal or Periampullary Cancer: Direct Quantitative PCR for ALU Repeats. *Clin. Chem.* **52**, 1062–1069 (2006).
- Ovchinnikov, I., Rubin, A. & Swergold, G. D. Tracing the LINEs of human evolution. *Proc. Natl. Acad. Sci.* **99**, 10522–10527 (2002).
- ISO. Biotechnology Requirements for evaluating the performance of quantification methods for nucleic acid target sequences qPCR and dPCR. ISO 20395:2019(en). https://www.iso.org/obp/ui#iso:std:iso:20395:ed-1:v1:en (Accessed August 2020).
- 356 19. Breitbach, S. *et al.* Direct Quantification of Cell-Free, Circulating DNA from Unpurified Plasma. *PLoS One* **9**, e87838 (2014).
- Jiang, P. & Lo, Y. M. D. The Long and Short of Circulating Cell-Free DNA and the Ins and Outs of Molecular Diagnostics. *Trends Genet.* **32**, 360–371 (2016).
- Holdenrieder, S., Burges, A., Reich, O., Spelsberg, F. W. & Stieber, P. DNA Integrity in Plasma and Serum of Patients with Malignant and Benign Diseases. *Ann. N. Y. Acad. Sci.* **1137**, 162–170 (2008).
- 362 22. Meddeb, R. et al. Quantifying circulating cell-free DNA in humans. Sci. Rep. 9, 5220 (2019).
- Boedecker, S. C. *et al.* Twelve-Week Internet-Based Individualized Exercise Program in Adults With Systemic Lupus Erythematosus: Protocol for a Randomized Controlled Trial. *JMIR Res. Protoc.* **9**, e18291 (2020).
- Lacroix, R. *et al.* Impact of pre-analytical parameters on the measurement of circulating microparticles: towards standardization of protocol. *J. Thromb. Haemost.* **10**, 437–46 (2012).
- 25. Piovesan, A. *et al.* On the length, weight and GC content of the human genome. *BMC Res. Notes* (2019). doi:10.1186/s13104-019-4137-z
- Forootan, A. *et al.* Methods to determine limit of detection and limit of quantification in quantitative realtime PCR (qPCR). *Biomol. Detect. Quantif.* **12**, 1–6 (2017).
- 372 27. Bustin, S. A. *et al.* The MIQE Guidelines: Minimum Information for Publication of Quantitative Real-373 Time PCR Experiments. *Clin. Chem.* **55**, 611–622 (2009).
- 28. Pierson-Perry, J. F. et al. Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures; Approved Guidance-Second Edition. EP17-A2. Clinical and Laboratory Standards Institute (2012).
- U.S. Department of Health and Human Services Food and Drug Administration Center for Drug
 Evaluation and Research. Bioanalytical Method Validation: Guidance for Industry. Bioanalytical Method
 Validation: Guidance for Industry (2018).
- Rapp, D., Scharhag, J., Wagenpfeil, S. & Scholl, J. Reference values for peak oxygen uptake: crosssectional analysis of cycle ergometry-based cardiopulmonary exercise tests of 10 090 adult German

perpetuity.

It is made available under a CC-BY 4.0 International license .

- volunteers from the Prevention First Registry. BMJ Open 8, e018697 (2018).
- 383 31. Meddeb, R., Pisareva, E. & Thierry, A. R. Guidelines for the Preanalytical Conditions for Analyzing Circulating Cell-Free DNA. *Clin. Chem.* **65**, 623–633 (2019).
- Thierry, A. R., El Messaoudi, S., Gahan, P. B., Anker, P. & Stroun, M. Origins, structures, and functions of circulating DNA in oncology. *Cancer Metastasis Rev.* **35**, 347–376 (2016).
- 387 33. Lehmann-Werman, R. *et al.* Identification of tissue-specific cell death using methylation patterns of circulating DNA. *Proc. Natl. Acad. Sci. U. S. A.* **113**, E1826–E1834 (2016).
- 389 34. Milosevic, D. *et al.* Applying Standard Clinical Chemistry Assay Validation to Droplet Digital PCR Quantitative Liquid Biopsy Testing. *Clin. Chem.* **64**, 1732–1742 (2018).
- 391 35. FDA. Bioanalytical Method Validation Guidance for Industry. (2018).
- 392 36. Fleischhacker, M. *et al.* Methods for isolation of cell-free plasma DNA strongly affect DNA yield. *Clin. Chim. Acta* (2011). doi:10.1016/j.cca.2011.07.011
- 394 37. Hellemans, J., Mortier, G., De Paepe, A., Speleman, F. & Vandesompele, J. qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data.

 396 Genome Biol. 8, R19 (2007).
- 397 38. Fleischhacker, M. & Schmidt, B. Pre-analytical issues in liquid biopsy-where do we stand? *J. Lab. Med.* 398 44, 117–142 (2020).
- 399 39. Lam, N. Y. L., Rainer, T. H., Chiu, R. W. K. & Lo, Y. M. D. EDTA Is a Better Anticoagulant than Heparin or Citrate for Delayed Blood Processing for Plasma DNA Analysis. *Clin. Chem.* **50**, 256–257 (2004).
- 40. Kang, Q. *et al.* Comparative analysis of circulating tumor DNA stability In K3EDTA, Streck, and CellSave blood collection tubes. *Clin. Biochem.* **49**, 1354–1360 (2016).
- 403 41. Xu, Y. *et al.* High levels of circulating cell-free DNA are a biomarker of active SLE. *Eur. J. Clin. Invest.* 48, e13015 (2018).
- 405 42. Fanouriakis, A. *et al.* 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. *Ann. Rheum. Dis.* **78**, 736–745 (2019).
- 407 43. Tug, S. *et al.* Exploring the Potential of Cell-Free-DNA Measurements After an Exhaustive Cycle-408 Ergometer Test as a Marker for Performance-Related Parameters. *Int. J. Sports Physiol. Perform.* **12**, 597– 409 604 (2017).
- 410 44. Korabecna, M. *et al.* Cell-free DNA in plasma as an essential immune system regulator. *Sci. Rep.* **10**, 17478 (2020).

Funding statement

- 414 The study was funded by the internal research funding of the Johannes Gutenberg-University of Mainz. The
- 415 funders had no role in study design, data collection and analysis, decision to publish, or preparation of the
- 416 manuscript.

412

413

417 Data availability

418 All data are available from the corresponding author on reasonable request.

419 Competing interests

The authors have declared no competing interest.